Robotic radiosurgery (RRS) was safe and effective for treating metastases of renal cell carcinoma (RCC) in a study that involved a highly selected group of patients, according to a presentation at IKCS Europe 2022.

Long-term outcomes appeared favorable, investigators concluded.

The study cohort included 50 patients with lung metastases, 44 with visceral metastases, and 16 with lymph node metastases who underwent image-guided RRS. Indications for treatment included oligometastatic disease defined as 5 or fewer lesions and oligoprogressive disease or limited systemic treatment options. At the time of the procedure, patients had a median age of 64 years. Of the 110 patients, 102 presented with clear cell RCC, 1 had papillary type 1, 3 had papillary type 2, and 3 had chromophobe histology, and 1 patient had a RCC with TFE3 translocation.


Continue Reading

Recurrent disease developed in 3 patients. The median progression-free survival was 13.0, 17.2, and 22.5 months for patients with lung, visceral, and lymph node metastases, respectively, investigator Severin Rodler, MD, of Klinikum der Universität München in Munich, Germany, reported. The median overall survival was 35.0, 65.7, and 36.8 months, respectively.

Adverse events (AEs) were limited to grade 1 or 2, although 1 patient experienced a grade 4 stroke and thrombosis. The most frequent AE was fatigue (8 patients), followed by pneumonitis (2 patients).

Reference

Schott M, Casuscelli J, Graser A, et al. Image-guided robotic radiosurgery for the treatment of metastases of renal cell carcinoma. Presented at IKCS Europe in Antwerp, Belgium. April 22-24, 2022. Poster 15.

This article originally appeared on Renal and Urology News